Handelsavisen
prelaunch
Companies Healthcare EHSI.PK
EH
EHSI.PK OTC Healthcare Providers & Services

Ehsi.Pk

$0,99
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-763,4 %
ROE
-146,9 %
Net margin
-762,1 %
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

EHSI.PK operates in the healthcare facilities and services industry, providing biotechnology-related services and equipment.

Business. EHSI.PK operates in the healthcare facilities and services industry, providing biotechnology-related services and equipment.

Classification99 %
SectorHealth Care
Industry groupHealthcare Providers & Services
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-146,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning EHSI.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to EHSI.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    EHSI.PK operates in the healthcare facilities and services industry, providing biotechnology-related services and equipment.

    Classification99 %
    SectorHealth Care
    Industry groupHealthcare Providers & Services
    AI synthesis
    GENERATED

    EHSI.PK exhibits a strong liquidity position, with a current ratio of 3.35, indicating that the company has more than three times the current assets to cover its current liabilities. The company holds $3.76 million in cash and equivalents, which is a significant portion of its total assets of $6.66 million. Despite this, the company reported negative operating cash flow of $2.94 million and free cash flow of $8.81 million, suggesting that it is not generating sufficient cash from operations to sustain its activities.

    Profitability metrics for EHSI.PK are negative, with a return on equity of -1.4688 and a return on assets of -1.1711, both significantly below the industry median for healthcare facilities and services. The company reported a net loss of $7.8 million, with operating income also in the red at $7.82 million. These figures indicate that the company is not currently profitable and is struggling to generate positive returns for its shareholders.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification reported. This lack of diversification increases the company's exposure to market-specific risks and could limit its growth potential. The company's revenue of $1.02 million is relatively small compared to its peers in the healthcare sector, and there is no indication of significant revenue growth in the near term.

    Looking ahead, EHSI.PK is expected to maintain its current revenue level, with no significant growth anticipated in the next fiscal year. The company's negative operating and free cash flows suggest that it may need to rely on external financing to fund its operations, although there are no immediate liquidity or dilution flags reported. The risk assessment indicates that the company has a low probability of dilution in the near term, but the lack of profitability and cash flow generation remains a concern.

    Recent filings and transcripts do not indicate any major events or strategic shifts for EHSI.PK. The company has not disclosed any new product launches, partnerships, or market expansions that could drive future growth. The absence of recent strategic developments suggests that the company may be in a holding pattern, with limited visibility into its long-term growth prospects.

    Key takeaways
    • EHSI.PK has a strong liquidity position with a current ratio of 3.35 and $3.76 million in cash and equivalents.
    • The company is not currently profitable, with a return on equity of -1.4688 and a return on assets of -1.1711.
    • Revenue is concentrated in a single business segment, with no geographic diversification reported.
    • The company is expected to maintain its current revenue level, with no significant growth anticipated in the next fiscal year.
    • There are no immediate liquidity or dilution flags, but the lack of profitability and cash flow generation remains a concern.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,99
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $5.3M
    Net cash
    $3.8M
    Current ratio
    3.4
    Debt / equity
    0.0
    ROA
    -1.2%
    ROE
    -1.5%
    Cash conversion
    38.0%
    CapEx / revenue
    -99.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryHealthcare Providers & Services16,0B node revenueOPCH 35,3%PACS 33,0%PRVA 13,3%SHC 7,3%NUTX 5,5%TOI 3,1%VMD 1,7%JYNT 0,3%Other 0,5%
    Source: company disclosures · own-taxonomy revenue-covered setEHSI 0,0% · rank #16 of 16

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs EHSI · multiples and returns
    OP
    OPCH
    Option Care Health Inc
    $22,09
    3,5B USD
    P/E
    16,5x
    vs self
    Div yield
    vs self
    ROE
    15,5 %
    vs self
    PA
    PACS
    Pacs Group Inc
    $38,00
    6,0B USD
    P/E
    25,2x
    vs self
    Div yield
    vs self
    ROE
    25,8 %
    vs self
    PR
    PRVA
    Privia Health Group Inc
    $23,90
    3,0B USD
    P/E
    123,6x
    vs self
    Div yield
    vs self
    ROE
    3,1 %
    vs self
    SH
    SHC
    Sotera Health Co
    $18,00
    5,1B USD
    P/E
    57,5x
    vs self
    Div yield
    vs self
    ROE
    12,9 %
    vs self
    NU
    NUTX
    NUTEX HEALTH INC.
    $176,00
    1,2B USD
    P/E
    9,7x
    vs self
    Div yield
    vs self
    ROE
    29,2 %
    vs self
    TO
    TOI
    Oncology Institute Inc
    $5,18
    527,8M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    372,2 %
    vs self
    VM
    VMD
    Viemed Healthcare Inc
    $11,00
    445,4M USD
    P/E
    26,7x
    vs self
    Div yield
    vs self
    ROE
    10,4 %
    vs self
    JY
    JYNT
    Joint Corp
    $8,21
    117,0M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -15,5 %
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-763,4 %Bottom quartile
    Net Margin-762,1 %Bottom quartile
    ROE-146,9 %Bottom quartile
    Capex / Rev-99,2 %Bottom quartile
    D/E0,00Above median
    Cash Conv0,38Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • EHSI.PK Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    1.7Kshares short+42.7% vs prior
    5.75days to cover
    69fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    EHSI.PKCanonical
    OTC · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -114.1%Derived (calculated)
    • Return on equity (FY 2025-12-31): -146.9%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -6.8%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 844.8%Derived (calculated)
    • Net margin (FY 2025-12-31): -762.1%Derived (calculated)
    • Gross margin (FY 2025-12-31): 11.5%Derived (calculated)
    • Return on assets (FY 2025-12-31): -117.1%Derived (calculated)
    • Current ratio (FY 2025-12-31): 3.35xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.25xDerived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 27.2%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 54.2%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -279.8%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -169.2%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -94.1%Derived (calculated)
    • Shareholders' equity (annual): USD 5.31MSEC XBRL filing
    • Cash & equivalents (annual): USD 3.76MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
    • Operating income (annual): USD -3.84MSEC XBRL filing
    • Gross profit (annual): USD 118KSEC XBRL filing
    • Total assets (annual): USD 6.66MSEC XBRL filing
    • Revenue (annual): USD 1.02MSEC XBRL filing
    • Net income (annual): USD -7.8MSEC XBRL filing
    • Pre-tax income (annual): USD -7.8MSEC XBRL filing
    • Operating cash flow (annual): USD -2.94MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage